Inotek Pharmaceuticals Corporation is a clinical-stage, drug development company with four distinct programs targeting fundamental mechanisms of cell injury, cell survival and inflammation. The Company has two Phase 1 programs, including a candidate for the treatment of glaucoma and a candidate to improve outcomes associated with high risk surgical procedures. Additionally, Inotek has two preclinical programs, a Flagellin monoclonal antibody program in development for the treatment of inflammatory bowel disease and gram negative infections and a PARP inhibitor program in development for use in oncology and other indications.
Inotek’s technologies were discovered and developed in-house and the Company’s product candidates are all best-in-class or first-in-class and are heavily supported by extensive preclinical validation. Inotek has built a first-class clinical development team to move the company’s four programs forward in clinical trials. The Company is privately held and is based in Beverly, MA.
